joe, I don't recall stating patents have been issued, but here are a couple of patent applications:
Influenza Therapeutic: http://tinyurl.com/q6vhs
RNAi-based therapeutics for allergic rhinitis and asthma : http://tinyurl.com/ok2ak
If you can point to any Alnylam patent applications in this area please post what you have. Ceteris paribus, those applications are in the catbird seat.
The relevant paragraph is the following:
"The intellectual property acquired from Galenea includes patent applications licensed from MIT that have early priority dates in the antiviral RNAi field. Nastech also acquired Galenea's research and intellectual property relating to pulmonary drug delivery technologies. Additionally, Nastech assumes Galenea's pending grant applications from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, and the Department of Defense to support the development of RNAi-based antiviral drugs."
I do not see any approved patents relating to RNAi therapeutics for flu, only pending applications. Therefore, I am not convinced that Alnylam missed out on anything here. Even the grants, which are usually only a couple of million, are not yet approved. I'm not saying Nastech will be excluded from the party, but by no means are they the sole player or out in front.
I do understand.I am not a cheerleader.ALNY will cross that bridge if necessary.The road ahead for this sector had best be paved with understanding and collaboration between the competing interests.If the major players all choose to go guns over the various patents time,money and energy will be lost.Hopefully the patents will be developed and treated as a currency and traded between companies as needed and relevant.The H5N1 virus (if it makes the leap)could hasten this cooperation due to the magnitude of the threat.
you need to understand ALNY HAD to get the Galenea IP to be in the game. They lost out.
Every dollar they now spend on avian flu is a dollar less they have to pursue something else. Go to the Nastech website and under the R & D section there is a page called Publications.
Look at the poster presentation produced jointly by Nastech and Galenea on Influenza that was presented in Hawaii last month.
I don't know what the timeline on the program is, but Galenea has grants in process that are way ahead of anything ALNY will apply for, even ignoring the animal study results Nastech already has.
Don't incorporate any Influenza program into ALNY's prospects if you want to avoid overvaluation here.
That's a great question. One that I was thinking of myself and I had to come to the conclusion that they have showed proof of principle, but kept it out of the public domain (i.e., never disclosed anything about it).
In the hayday of early sequencing, people just patented sequences without anything else. The patent office put the stop on that, and demanded knowledge of what the gene was responsible for. Then the bar was raised to showing that you could use the gene (or part of it) to do something useful... cure cancer, etc. Then you would be granted a patent for that gene for curing cancer with part of it. If someone than came along and showed that they could use it for, let's say, lengthening your manlyness, they could be granted a patent for that use which would not violate the first patent.
So I think they had this in the works for a while and got a patent specifically for an RNAi-based treatment only.
Yes, but it seems to me they are trying to do an end run around Alnylam's patent estate. They are simply identifying a target that is potentially treatable with siRNA and then saying that they own any pharma that comes out of that. Heck I might as well take out a patent on the phrase "gene silencing."
Just like how companies used to patent DNA sequences with no known function. The patent office will grant a patent....but the validity of the patent and or strength are what is more important.
For example if sirna patents the silencing of gene A to cure disease B, another company could still work around this in many ways depending on how strong the claims are in the patent and the data that backs them up.
I am an RNAI shareholder, but my biggest position is in ALNY. The fact ALNY goes down suggests traders are rotating between the two and that some people got scared RNAI might get the jump on ALNY, simply because they do not understand the patent process and that a patent is not a panacea.
ALNY by far have the strongest RNAi patent estate.
The drop today for ALNY on great validating news for RNA interference makes no sense.
Its all good to see another major pharma deal into RNAi.
It was my guess that GSK (as one of the last major pharmas not yet aligned with an RNAi company) might partner BLT. So I was partially right about GSK, just wrong about RNAI versus BLT. Nevertheless this deal is good news for all the RNAi companies.
Hopefully BLT will announce a partnering deal soon and we can all expect 2006-2007 to be a watershed year for RNA interference.
See my bold prediction for 2007.
Why am I not suprised you would be wrong again?
Many in the industry have believed RNAI has a patent estate superior to ALNY. The reason for this was demonstrated yesterday.
Maraganore and Robin have been carrying on like a couple of boys from different frats after a long night of drinking. I don't expect that to end anytime soon.
Novartis misplaced their wager.